How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

779 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Galantamine Alleviates Inflammation and Other Obesity-Associated Complications in High-Fat Diet–Fed Mice (PubMed)

Galantamine Alleviates Inflammation and Other Obesity-Associated Complications in High-Fat Diet–Fed Mice Obesity, a serious and growing health threat, is associated with low-grade inflammation that plays a role in mediating its adverse consequences. Previously, we have discovered a role for neural cholinergic signaling in controlling inflammation, and demonstrated that the cholinergic agent galantamine suppresses excessive proinflammatory cytokine release. The main objective of this study (...) was to examine the efficacy of galantamine, a clinically-approved drug, in alleviating obesity-related inflammation and associated complications. After 8 wks on a high-fat diet, C57BL/6J mice were treated with either galantamine (4 mg/kg, intraperitoneally [i.p.]) or saline for 4 wks in parallel with mice on a low-fat diet and treated with saline. Galantamine treatment of obese mice significantly reduced body weight, food intake, abdominal adiposity, plasma cytokine and adipokine levels, and significantly

Full Text available with Trip Pro

2011 Molecular Medicine

82. Galantamine Effects on Nicotine Responses in Smokers

Galantamine Effects on Nicotine Responses in Smokers Galantamine Effects on Nicotine Responses in Smokers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Galantamine Effects on Nicotine Responses in Smokers (...) University Study Details Study Description Go to Brief Summary: This will be a 2-4 week double-blind, placebo-controlled study. Twenty four male and female smokers will first have two 4-day treatment periods, in which they will be randomized to galantamine (8 mg/day) or placebo. These treatment periods will be separated by a 3 to 14 day washout period. During the first 3-days of each treatment period, smokers will have daily clinic visits, where they will receive study medications and any adverse effects

2011 Clinical Trials

83. Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition

Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Galantamine (...) Study Details Study Description Go to Brief Summary: Galantamine Hydrobromide Tablets, Bioequivalence study of Dr. Reddy's under Fed condition. Condition or disease Intervention/treatment Phase Fed Drug: Reminyl Phase 1 Detailed Description: Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories, ltd. and Janssen Pharmaceutical Products, l.P. (Reminyl®)4 mg Galantamine HBr Tablets in Healthy Adult Male Volunteers under Fed Conditions Study Design Go

2011 Clinical Trials

84. Galantamine Bioequivalence Study of Dr. Reddy's Under Fasting Condition

Galantamine Bioequivalence Study of Dr. Reddy's Under Fasting Condition Galantamine Bioequivalence Study of Dr. Reddy's Under Fasting Condition - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Galantamine (...) Limited Study Details Study Description Go to Brief Summary: Galantamine Hydrobromide Tablets, Bioequivalence study of Dr. Reddy's under Fasting condition. Condition or disease Intervention/treatment Phase Fasting Drug: Reminyl Phase 1 Detailed Description: Comparative, Randomized, Single-Dose. 2-way Crossover Bioavailability Study of Dr.Reddy's laboratories, ltd. and Janssen Pharmaceutical Products. L.P. (Reminyte®)4 mg Galantamine HBr Tablets In Healthy Adult Male Volunteers under fasting Conditions

2011 Clinical Trials

85. Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01478633

2011 Clinical Trials

86. Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment

Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment (COGICRehab) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01508494 Recruitment Status : Unknown Verified April 2015 by Institut National de la Santé Et de la Recherche Médicale, France. Recruitment status was: Recruiting

2011 Clinical Trials

87. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. (PubMed)

Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Galantamine, a reversible cholinesterase inhibitor with effects on nicotinic receptors, has shown mixed effects on cognitive impairments in patients with schizophrenia. Given these mixed results we examined whether galantamine compared to adjunctive placebo may improve cognitive functions in patients treated concomitantly with a long acting atypical antipsychotic.The parent study (...) was a 52-week double-blind, randomized study of treatment with long-acting injectable risperidone 25mg or 50mg every two weeks. Adjunctive galantamine or placebo treatment was administered from Month 6 to 12. Outcome measures were neurocognitive, psychopathology, social and quality of life functions. Patients were randomized to blinded galantamine up to 24mg/day or matching placebo tablets. All patients were maintained on their randomized long-acting injectable risperidone regimen for the duration

2011 Schizophrenia research

88. Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients. (PubMed)

Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients. The effects of galantamine (16 to 24 mg/day) treatment on brain functional activities (blood flow and glucose metabolism) were examined in 18 patients with mild Alzheimer's disease (AD) in relation to brain acetylcholinesterase (AChE) activity and nicotinic receptors and cognitive function. The study consisted of an initial double-blind phase of three months (short-term (...) patient in order to follow changes in cognition during the treatment period. Throughout the study, different cortical areas showed significant increases in rCBF after galantamine treatment. rCBF positively correlated with AChE activity, nicotinic receptors and cognition. In addition to these positive changes, an increase in rCMRglc in the frontal brain region and stabilization in other cortical areas was observed after 12 months galantamine treatment. This stabilization in rCMRglc was also correlated

2011 Journal of Alzheimer's disease : JAD

89. Galantamine improves sustained attention in chronic cocaine users. (PubMed)

Galantamine improves sustained attention in chronic cocaine users. Chronic cocaine users are known to have cognitive deficits that are predictive of poor treatment response. Whether these deficits improve with medications targeting specific cognitive functions has not been examined in previous studies. The goal of this study was to evaluate galantamine's efficacy on selected cognitive outcomes, including measures of sustained attention, response inhibition, and attentional bias in recently (...) abstinent cocaine users. Galantamine, a reversible and competitive inhibitor of acetylcholinesterase, is used clinically in the treatment of Alzheimer's dementia. In a randomized, double-blind, parallel-group study, 34 participants were randomized to galantamine (8 mg/day) or placebo treatment for 10 days. Cognitive and self-report mood measures were obtained at baseline and on Days 5 and 10 after the initiation of treatment. Galantamine treatment, compared to placebo, improved the reaction time, F(2

Full Text available with Trip Pro

2011 Experimental and clinical psychopharmacology

90. Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment. (PubMed)

Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment. To evaluate the effects of galantamine withdrawal, and compare this with uninterrupted therapy, two 6-week double-blind withdrawal studies (Studies 1 and 2) were performed. These enrolled individuals who had completed one of two 3- or 5-month randomized clinical trials (parent trials) involving patients with mild to moderate Alzheimer's disease (AD). In Study 1 (GAL (...) -USA-11; n'723), patients continuously treated with galantamine 16 mg/day exhibited a mean (± standard error [SE]) improvement in 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale score of 1.8 (± 0.46) points at Week 6 compared with the parent trial baseline, (p < 0.001 vs placebo; observed cases analysis). Over the same period, patients switched from galantamine to placebo and those who had received continuous placebo, exhibited mean (± SE) deteriorations of 0.7 (± 0.49

2011 Current Alzheimer research

91. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. (PubMed)

Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. Galantamine improved symptoms in Alzheimer's disease (AD) patients after 5 to 6 months of treatment. To examine long-term outcomes, this study assessed if continuing of galantamine treatment beyond 12 months delayed further cognitive deterioration. It consisted of two phases: an open label (OL) phase (12 months (...) ), followed by a double blind, randomized, placebo controlled withdrawal phase (up to 24 months). Subjects with mild to moderate AD were included in the study and titrated up to 16 mg/day of galantamine. Subjects were eligible to enter the double blind phase if a cognitive decline of <4 points on AD Assessment Scale-cognitive subscale (ADAS-cog)/11 was recorded at the end of the OL phase. The differences between galantamine and placebo in time to dropout were estimated using the Cox proportional hazard

Full Text available with Trip Pro

2011 Journal of Alzheimer's disease : JAD

92. Development and in vivo evaluation of novel monolithic controlled release compositions of galantamine hydrobromide as against reservoir technology. (PubMed)

Development and in vivo evaluation of novel monolithic controlled release compositions of galantamine hydrobromide as against reservoir technology. The objective of this study is to develop and in vivo evaluation of novel monolithic matrix mini tablets approach to control the release of galantamine hydrobromide (GAH) in comparison with desired release profile to the Innovator formulation Razadyne(®) ER capsules. The direct compression method was employed for preparation of matrix mini tablets

2011 Pharmaceutical development and technology

93. Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study. (PubMed)

Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study. In Alzheimer's disease (AD), it is important to consider long-term effects, not only in patients receiving treatment, but also in subjects in whom therapy has been discontinued. The present analysis evaluates the long-term effects of galantamine on cognitive function in AD in terms of Mini-Mental State Examination (MMSE) scores for up to 7 years, using both clinical (...) data and epidemiological modeling. Consideration is given not only to patients continuing to receive galantamine therapy, but also to those who stop this treatment. In a retrospective review of medical notes, re-contacted study investigators obtained data from 258 patients originally recruited into three previously described randomized clinical trials involving galantamine: two placebo-controlled trials in mild-to-moderate AD (of 3 and 6 months' duration, followed by open-label extensions

2011 Journal of Alzheimer's disease : JAD

94. The effect of galantamine on the blood pressure of the rat. (PubMed)

The effect of galantamine on the blood pressure of the rat. 4380412 1966 11 28 2018 11 13 0366-0826 26 2 1966 Feb British journal of pharmacology and chemotherapy Br J Pharmacol Chemother The effect of galantamine on the blood pressure of the rat. 295-301 Chrusciel M M Varagić V V eng Comparative Study Journal Article England Br J Pharmacol Chemother 0154627 0366-0826 0 Ganglionic Blockers 0 Parasympatholytics 0 Sympatholytics 0D3Q044KCA Galantamine IM Adrenalectomy Animals Blood Pressure drug (...) effects Female Galantamine pharmacology Ganglionic Blockers pharmacology Male Parasympatholytics pharmacology Rats Sympatholytics pharmacology 1966 2 1 1966 2 1 0 1 1966 2 1 0 0 ppublish 4380412 PMC1510659 J Physiol. 1948 Mar 15;107(2):162-4 16991795 Br J Pharmacol Chemother. 1964 Aug;23:34-42 14206267 J Physiol. 1953 Jan;119(1):43-57 13035716 Br J Pharmacol Chemother. 1964 Aug;23:80-9 14206271 Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1957;230(5):448-56 13526758 J Pharmacol Exp Ther. 1962 Jan

Full Text available with Trip Pro

1966 British journal of pharmacology and chemotherapy

95. Galantamine in the Treatment of Minor Depression With Mild to Moderate Alzheimer's Dementia in an Elderly Woman (PubMed)

Galantamine in the Treatment of Minor Depression With Mild to Moderate Alzheimer's Dementia in an Elderly Woman 20944777 2012 08 23 2018 11 13 1555-211X 12 3 2010 Primary care companion to the Journal of clinical psychiatry Prim Care Companion J Clin Psychiatry Galantamine in the treatment of minor depression with mild to moderate Alzheimer's dementia in an elderly woman. 10.4088/PCC.09l00905gry PCC.09l00905 Alagiakrishnan Kannayiram K Department of Medicine, Division of Geriatric Medicine

Full Text available with Trip Pro

2010 Primary Care Companion to the Journal of Clinical Psychiatry

96. The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease

The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2010 Clinical Trials

97. Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01190761 Recruitment Status : Completed

2010 Clinical Trials

98. Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01190748 Recruitment Status

2010 Clinical Trials

99. Galantamine Treatment for Nonfluent Aphasia in Stroke Patients

Galantamine Treatment for Nonfluent Aphasia in Stroke Patients Galantamine Treatment for Nonfluent Aphasia in Stroke Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Galantamine Treatment (...) by: University of North Carolina, Chapel Hill Study Details Study Description Go to Brief Summary: Cognitive impairment after stroke is common and has a major effect on morbidity and quality of life. Acetylcholinesterase inhibitors have demonstrated benefit in vascular dementia, but efficacy in treating more circumscribed cognitive deficits following stroke, such as aphasia, has not been systematically investigated. This study evaluated the efficacy of Galantamine (Reminyl) in subjects with chronic, stable

2010 Clinical Trials

100. Effects of Galantamine on Cognition

Effects of Galantamine on Cognition Effects of Galantamine on Cognition - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effects of Galantamine on Cognition The safety and scientific validity of this study (...) Description Go to Brief Summary: Schizophrenia is a chronic disorder with onset of psychosis occurring in late teen early twenties, with cognitive impairments and negative symptoms frequently emerging much earlier. Such cognitive impairments and negative symptoms but much milder are also observed in high-risk groups (such as relatives of schizophrenia patients), who may or may not develop the full blown psychotic disorder. Our study plans to recruit such non-ill subjects to test the effects of galantamine

2010 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>